Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2024

View source ↗

Summary

The CHMP recommended Leqembi (lecanemab) for the treatment of early Alzheimer's disease, indicating EMA support ahead of final authorization.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• LEQEMBI (lecanemab)

Snippet

Leqembi (lecanemab) recommended for treatment of early Alzheimer’s disease